Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer

Yin Cao, Katharina Nimptsch, Irene M. Shui, Elizabeth A Platz, Kana Wu, Michael N. Pollak, Stacey A. Kenfield, Meir J. Stampfer, Edward L. Giovannucci

Research output: Contribution to journalArticle

Abstract

Insulin-like growth factor (IGF)-1 is associated with a higher risk of prostate cancer. IGF-binding protein (IGFBP)-1, a marker for insulin activity, also binds IGF-1 and inhibits its action. Data on IGFBP-1 and prostate cancer risk are sparse and whether the IGF and insulin axes interact to affect prostate cancer carcinogenesis is unknown. We evaluated the independent and joint influence of prediagnostic plasma levels of IGFBP-1 (fasting) and IGF-1 on risk of prostate cancer among 957 cases and 1,021 controls with fasting levels of IGFBP-1 and 1,709 cases and 1,778 controls with IGF-1 nested within the Health Professionals Follow-up Study. Unconditional logistic regression adjusting for matching factors was used to estimate the odds ratio (OR) and 95% confidence interval (CI). Higher prediagnostic fasting IGFBP-1 levels were associated with lower risk of prostate cancer (highest vs. lowest quartile OR = 0.67, 95% CI 0.52-0.86, ptrend = 0.003), which remained similar after adjusting for IGF-1. Prediagnostic IGF-1 was associated with increased risk of prostate cancer (highest vs. lowest quartile OR = 1.28, 95% CI = 1.05-1.56, ptrend = 0.01). The associations with each marker were primarily driven by lower-grade and non-advanced prostate cancer. Being low in IGFBP-1 and high in IGF-1 did not confer appreciable additional risk (pinteraction = 0.42). In summary, prediagnostic fasting IGFBP-1 may influence prostate cancer carcinogenesis. Being low in IGFBP-1 or high in IGF-1 is sufficient to elevate the risk of prostate cancer.

Original languageEnglish (US)
Pages (from-to)2418-2426
Number of pages9
JournalInternational Journal of Cancer
Volume136
Issue number10
DOIs
StatePublished - May 15 2015

Fingerprint

Insulin-Like Growth Factor Binding Protein 1
Somatomedins
Blood Proteins
Prostatic Neoplasms
Fasting
Odds Ratio
Confidence Intervals
Carcinogenesis
Insulin
Joints
Logistic Models

Keywords

  • IGF-1
  • IGFBP-1
  • insulin
  • prostate cancer
  • risk

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cao, Y., Nimptsch, K., Shui, I. M., Platz, E. A., Wu, K., Pollak, M. N., ... Giovannucci, E. L. (2015). Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. International Journal of Cancer, 136(10), 2418-2426. https://doi.org/10.1002/ijc.29295

Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. / Cao, Yin; Nimptsch, Katharina; Shui, Irene M.; Platz, Elizabeth A; Wu, Kana; Pollak, Michael N.; Kenfield, Stacey A.; Stampfer, Meir J.; Giovannucci, Edward L.

In: International Journal of Cancer, Vol. 136, No. 10, 15.05.2015, p. 2418-2426.

Research output: Contribution to journalArticle

Cao, Y, Nimptsch, K, Shui, IM, Platz, EA, Wu, K, Pollak, MN, Kenfield, SA, Stampfer, MJ & Giovannucci, EL 2015, 'Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer', International Journal of Cancer, vol. 136, no. 10, pp. 2418-2426. https://doi.org/10.1002/ijc.29295
Cao, Yin ; Nimptsch, Katharina ; Shui, Irene M. ; Platz, Elizabeth A ; Wu, Kana ; Pollak, Michael N. ; Kenfield, Stacey A. ; Stampfer, Meir J. ; Giovannucci, Edward L. / Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. In: International Journal of Cancer. 2015 ; Vol. 136, No. 10. pp. 2418-2426.
@article{46e6f58cd04e4f48a20d6d4f0c710cb7,
title = "Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer",
abstract = "Insulin-like growth factor (IGF)-1 is associated with a higher risk of prostate cancer. IGF-binding protein (IGFBP)-1, a marker for insulin activity, also binds IGF-1 and inhibits its action. Data on IGFBP-1 and prostate cancer risk are sparse and whether the IGF and insulin axes interact to affect prostate cancer carcinogenesis is unknown. We evaluated the independent and joint influence of prediagnostic plasma levels of IGFBP-1 (fasting) and IGF-1 on risk of prostate cancer among 957 cases and 1,021 controls with fasting levels of IGFBP-1 and 1,709 cases and 1,778 controls with IGF-1 nested within the Health Professionals Follow-up Study. Unconditional logistic regression adjusting for matching factors was used to estimate the odds ratio (OR) and 95{\%} confidence interval (CI). Higher prediagnostic fasting IGFBP-1 levels were associated with lower risk of prostate cancer (highest vs. lowest quartile OR = 0.67, 95{\%} CI 0.52-0.86, ptrend = 0.003), which remained similar after adjusting for IGF-1. Prediagnostic IGF-1 was associated with increased risk of prostate cancer (highest vs. lowest quartile OR = 1.28, 95{\%} CI = 1.05-1.56, ptrend = 0.01). The associations with each marker were primarily driven by lower-grade and non-advanced prostate cancer. Being low in IGFBP-1 and high in IGF-1 did not confer appreciable additional risk (pinteraction = 0.42). In summary, prediagnostic fasting IGFBP-1 may influence prostate cancer carcinogenesis. Being low in IGFBP-1 or high in IGF-1 is sufficient to elevate the risk of prostate cancer.",
keywords = "IGF-1, IGFBP-1, insulin, prostate cancer, risk",
author = "Yin Cao and Katharina Nimptsch and Shui, {Irene M.} and Platz, {Elizabeth A} and Kana Wu and Pollak, {Michael N.} and Kenfield, {Stacey A.} and Stampfer, {Meir J.} and Giovannucci, {Edward L.}",
year = "2015",
month = "5",
day = "15",
doi = "10.1002/ijc.29295",
language = "English (US)",
volume = "136",
pages = "2418--2426",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer

AU - Cao, Yin

AU - Nimptsch, Katharina

AU - Shui, Irene M.

AU - Platz, Elizabeth A

AU - Wu, Kana

AU - Pollak, Michael N.

AU - Kenfield, Stacey A.

AU - Stampfer, Meir J.

AU - Giovannucci, Edward L.

PY - 2015/5/15

Y1 - 2015/5/15

N2 - Insulin-like growth factor (IGF)-1 is associated with a higher risk of prostate cancer. IGF-binding protein (IGFBP)-1, a marker for insulin activity, also binds IGF-1 and inhibits its action. Data on IGFBP-1 and prostate cancer risk are sparse and whether the IGF and insulin axes interact to affect prostate cancer carcinogenesis is unknown. We evaluated the independent and joint influence of prediagnostic plasma levels of IGFBP-1 (fasting) and IGF-1 on risk of prostate cancer among 957 cases and 1,021 controls with fasting levels of IGFBP-1 and 1,709 cases and 1,778 controls with IGF-1 nested within the Health Professionals Follow-up Study. Unconditional logistic regression adjusting for matching factors was used to estimate the odds ratio (OR) and 95% confidence interval (CI). Higher prediagnostic fasting IGFBP-1 levels were associated with lower risk of prostate cancer (highest vs. lowest quartile OR = 0.67, 95% CI 0.52-0.86, ptrend = 0.003), which remained similar after adjusting for IGF-1. Prediagnostic IGF-1 was associated with increased risk of prostate cancer (highest vs. lowest quartile OR = 1.28, 95% CI = 1.05-1.56, ptrend = 0.01). The associations with each marker were primarily driven by lower-grade and non-advanced prostate cancer. Being low in IGFBP-1 and high in IGF-1 did not confer appreciable additional risk (pinteraction = 0.42). In summary, prediagnostic fasting IGFBP-1 may influence prostate cancer carcinogenesis. Being low in IGFBP-1 or high in IGF-1 is sufficient to elevate the risk of prostate cancer.

AB - Insulin-like growth factor (IGF)-1 is associated with a higher risk of prostate cancer. IGF-binding protein (IGFBP)-1, a marker for insulin activity, also binds IGF-1 and inhibits its action. Data on IGFBP-1 and prostate cancer risk are sparse and whether the IGF and insulin axes interact to affect prostate cancer carcinogenesis is unknown. We evaluated the independent and joint influence of prediagnostic plasma levels of IGFBP-1 (fasting) and IGF-1 on risk of prostate cancer among 957 cases and 1,021 controls with fasting levels of IGFBP-1 and 1,709 cases and 1,778 controls with IGF-1 nested within the Health Professionals Follow-up Study. Unconditional logistic regression adjusting for matching factors was used to estimate the odds ratio (OR) and 95% confidence interval (CI). Higher prediagnostic fasting IGFBP-1 levels were associated with lower risk of prostate cancer (highest vs. lowest quartile OR = 0.67, 95% CI 0.52-0.86, ptrend = 0.003), which remained similar after adjusting for IGF-1. Prediagnostic IGF-1 was associated with increased risk of prostate cancer (highest vs. lowest quartile OR = 1.28, 95% CI = 1.05-1.56, ptrend = 0.01). The associations with each marker were primarily driven by lower-grade and non-advanced prostate cancer. Being low in IGFBP-1 and high in IGF-1 did not confer appreciable additional risk (pinteraction = 0.42). In summary, prediagnostic fasting IGFBP-1 may influence prostate cancer carcinogenesis. Being low in IGFBP-1 or high in IGF-1 is sufficient to elevate the risk of prostate cancer.

KW - IGF-1

KW - IGFBP-1

KW - insulin

KW - prostate cancer

KW - risk

UR - http://www.scopus.com/inward/record.url?scp=84924311398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924311398&partnerID=8YFLogxK

U2 - 10.1002/ijc.29295

DO - 10.1002/ijc.29295

M3 - Article

C2 - 25348852

AN - SCOPUS:84924311398

VL - 136

SP - 2418

EP - 2426

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -